

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/SE04/001883

International filing date: 16 December 2004 (16.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: SE
Number: 0400191-3
Filing date: 30 January 2004 (30.01.2004)

Date of receipt at the International Bureau: 03 January 2005 (03.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

Länk till Patent- och reg.verket

+46 31630263

-61- 3 0

Huvudfoxen Kassan

7

It is clear that even though it is well established in the scientific community that periodontal disease is a multi-factorial disease no one has yet developed a test to analyse both bacterial and host derived products in a sample.

The test kit may also comprise a third detection assay comprising at least a third affinity ligand having a binding site for binding of a third substance originating from bacteria or from the immune or inflammatory system of the patient as defined above, preferably from bacteria, and may in some embodiments even comprise further detection assays for binding of additional substances.

Preferably, the first affinity ligand is an antibody
15 exhibiting selective binding of said first substance, and
the second affinity ligand is an antibody exhibiting se-
lective binding of said second substance.

The use of antibodies is advantageous over other methods (e.g. enzymatic methods) since antibodies, once developed and tested for cross-reactivity, are highly specific for their target and are able to detect chemical substances other than enzymes, e.g. toxins and cytokines. Furthermore, methods for development of new antibodies against new antigens are well known to those skilled in the art.

Preferably said detection assays in the test kit according to the present invention comprises immunochromatographic assays.

Among the advantages of using immunochromatographic assays/methods is that they are easily produced and used, have a long shelf-life, yields a quick answer and can be designed to be very specific for the substances intended to be detected.

Said test kit further preferably comprises a support
35. provided with a sample reservoir for receiving a sample,
wherein said first and second detection assays are ar-
ranged on said support in contact with said sample reser-

Ink. t. Patient- och reg.verket +46 31630263

-01-30

Huvudfaxen Kassan

11

oides forsythus or a toxin, more preferably the leukotoxin from *Actinobacillus actinomycetemcomitans*.

The presence of virulence products may trigger an inflammatory response and the immune system of the host, thus recruiting defence system cells, e.g. polymorphonuclear (PMN) leukocytes, to the site of infection.

The leukocytes cannot cope with the high amounts of bacteria and bacterial products at the infected site and enzymes from the leukocyte granulates are released into the periodontal pocket. These enzymes, originally aimed at killing the invading bacteria, are highly destructive to the surrounding tissues. Human neutrophil elastase has been shown to degrade many of the supportive tissues surrounding a tooth. Elastase is often found bound to its protease inhibitor (α -1 antitrypsin) in the periodontal pocket. However, the protease from *P. gingivalis* has been shown to degrade the protease inhibitors α -1 antitrypsin and α -2 macroglobulin in human serum, leaving elastase in its highly destructive form in the periodontal or peri-implant pocket.

As used herein, substances "originating from the immune or inflammatory system" refers to substances that originates from cells involved in the immune or inflammatory system. Such substances may be secreted from said cells, or may originate from lysis of such cells, for example to orchestrate the immune and inflammatory response or to remodel the tissue or killing the invading bacteria.

The second substance may be a leukocyte product, such as a natural serine protease, preferably human neutrophil elastase or a cytokine, such as an interleukin preferably chosen from among interleukin-1 β , interleukin-6 and interleukin-8, or an inflammatory mediator, preferably tumour necrosis factor- α or possibly prostaglandin E₂.

Most preferably, said second substance is human neutrophil elastase.

04 01/30 14:25 FAX +46 31630263

AWAPATENT

→ PRV KASSAN

016

+46 31630263

Ink t. Patent- och reg.verket

...-01-30

Huvudkassen Kassan

14

The invention also relates to a method for diagnosing periodontal diseases and/or predicting the risk for progress of said diseases, said method comprising analyzing a sample from the oral cavity of a patient for the presence of at least a first substance originating from bacteria and the presence of a second substance originating from the immune or inflammatory system of the patient.

In the method according to the present invention, sample from the oral cavity of a patient and the first and second substances are as defined above.

Also in some instances, the diagnostic method according to the present invention further comprises the step of detecting the presence of additional substances as defined above in said sample.

In preferred embodiments of the diagnosis method according to the present invention, said first method comprises using a first antibody exhibiting selective binding of said first substance and said second method comprises using a second antibody exhibiting selective binding of said second substance, wherein said antibodies are as defined above.

Most preferably at least one of said first and second methods comprises using an immunochromatographic method.

Other detection methods suitable for use with the methods according to the present invention may be based on one out of several immunological methods. Such methods include, but are not limited to, immunochromatographic methods, immunometric methods, immunoagglutination methods, fluoroimmunological methods, immunoluminescence methods, turbidimetric immunological methods, ELISA and nephelometric methods.

35 Preferred embodiments

Preferably a test kit according to the invention, as illustrated in figure 1, comprises two immunochroma-

'04 01/30 14:25 FAX +46 31630263

A W A P A T I E A N T

→ PRV KASSAN

4017

Ink t. Patent- och reg.verket +46 31630263

-01- 30

Huvudlinjen Kassan

15

to graphic detection assays 1, 2 arranged on a support 3 equipped with a sample reservoir 4 for receiving a sample. The two detection assays 1, 2 are arranged, directly or via a removably arranged separating means 5, in contact with the sample reservoir 4.

5 tact with the sample reservoir 4.

The sample reservoir 4 is preferably formed in the support material. The support 3 can be made of several different material, such as plastic, paper, carton or combinations thereof, such as paper laminated with plastic.

10 combinations thereof, said assays being arranged in a support 3
tic. The detection assays 1, 2 are fixed on the support 3
in such a manner that the sample receiving areas of each
assay is, directly or via a removably arranged separating
means 5, in contact with the sample reservoir 4. Said
separating means 5 may be a removable foil covering the
sample receiving areas on the assays, a dam separating
15 the reservoir from the assays, etc.

than comprise additional buffers for

The kit may further comprise additional buffers for dilution and adaptation of said sample for said detection assays and at least one sampling device for obtaining the sample to be analysed. The type of sampling device suitable for use may depend on the type of sample to be analysed. For example gingival crevicular fluid is a viscous fluid and can easily be collected by a small brush, a dental floss, a paper point or a disposable pipette.

25 Other sampling devices for obtaining a saliva or mouth
rinse sample are known to those skilled in the art. Preferably the buffer is kept separately from the sample reservoir in a buffer reservoir, such as a separate flask, an additional reservoir formed on the support or by providing the buffer in a puncturable bag placed in the sample reservoir.

After a sample is obtained, it is preferably mixed with buffer to obtain the pH, ionic strength and viscosity suitable for the detection assays. After mixing, the sample is transferred to the sample reservoir, and is thus, optionally by removing the separating means,

• 04 01/30 14:25 FAX +46 31630263

AWAPATIANT

→ PRV KASSAN

4020

Ink i Patr.n- och reg.verket

+46 31630263

2 3 8

Huvudtaven Kassan

18

(Nunc, Roskilde, Denmark) containing 100 µl 0,85% NaCl. The samples were frozen immediately at -20°C and within 6 hours at -80°C, and stored until assayed. For the microbial analysis 3 paper points were inserted consecutively into the periodontal pocket until resistance was met and left in place for 15 seconds. The points were pooled into a vial containing 10 glass beads, 3 mm in diameter, and 3,3 ml of VMGA III transport medium, aerobically prepared and stored. The samples were processed within 24 hours. Bacteria were grown on enriched Brucella agar plates and identified by appropriate methods.

For the study of appropriate cut-off values for a diagnostic test we studied elastase from human neutrophils and arg-gingipain from *P. gingivalis* using selective substrates.

The first set of the duplicate samples was used for the enzyme assays. All samples were thawed on ice and centrifuged for 3 minutes at 13,000 x g.

The enzyme substrate for determining arg-gingipain from *P. gingivalis* was N-benzoyl-L-arginine-p-nitroanilide (BAPNA) with a final concentration of 1 mM in the assay buffer containing 5 % DMSO. The assay buffer was 0.1 M Tris-HCl containing 5 mM CaCl₂, pH 7.5, with 50 mM glycyl-glycine (as reported earlier by the inventors in patent US 5,981,164 gly-gly stimulates BAPNA selectively in the presence of arg-gingipain) and 5 mM L-cysteine. Ten µL of the sample was preincubated for 15 minutes with 140 µL of the assay buffer in the well of a 96-well microtiter plate, precoated with bovine serum albumin, before 50 µL of the substrate was added. The plate was incubated at 37°C in a humid chamber, and the release of pNA was followed spectrophotometrically by OD₄₀₅ readings, using a microtiter plate reader, every few hours from 12 to 36 hours. One unit of activity was equal to the amount of enzyme which cleaved 1 nmol of the substrate during one hour of incubation.

+46 31630263

Lhk f. Patient- och reg.verket

-C1- 3 0

Huvudtaxon Kassan

20

Results

<u>Elastase</u>		Attachment loss	Attachment gain or zero
Positive test (Elastase >20 ng)		3	2
Negative test (Elastase ≤20 ng)		3	27

5 Elastase as a predictor of further attachment loss yielded a sensitivity of 50% and a specificity of 93%. A p-value of 0.0264* was calculated using Fisher's exact test.

<u>Arg-gingipain</u>		Attachment loss	Attachment gain or zero
Positive test (arg-gingipain >0,27 U)		6	13
Negative test (arg-gingipain ≤0,27 U)		0	16

10

Arg-gingipain as a predictor of further attachment loss yielded a sensitivity of 100% and a specificity of 55%. A p-value of 0.0216* was calculated using Fisher's exact test.

15 For elastase and arg-gingipain alone either the sensitivity or the specificity had to be sacrificed. This prompted us to investigate the combination of the two enzymes. We investigated new cut-off levels for the two enzymes to find that the detection limit for elastase should be 2 ng per site and 0,30 units for arg-gingipain.

'04 01/30 14:26 FAX +46 31630263

AWAPATEANT

→ PRV KASSAN

4023

+46 31630263

Ink. t. Patent- och reg.verket

2014-07-30

21

Huvudtakten Kassan

<u>Combination</u>		Attachment loss	Attachment gain or zero
Positive test (Elastase >2 ng <u>and</u> arg-gingipain >0,30 U)		5	3
Negative test (Elastase ≤2 ng <u>or</u> arg-gingipain ≤0,30 U)		1	26

The combination of elastase and arg-gingipain as a predictor of further attachment loss yielded a

5 sensitivity of 83% and a specificity of 90%. A p-value of
less than 0,001*** was calculated using Fisher's exact
test. This limited data shows that the combination of
elastase and arg-gingipain as a marker for periodontal
disease yields a statistically more significant test
than either of the enzymes alone.

10 than either of the enzymes alone.

+46 31630263

Ink t. Patient- och ren.verket

year -01- 3 0

22 Huvudkuren Kassan

References

- Armitage G.C. (2003) Position paper: Diagnosis of Periodontal Diseases. *Journal of Periodontology* 74, 1237-1247.
- 5 Eley B.M. and Cox S.W. (1996) Correlation Between Gingivain/Gingipain and Bacterial Dipeptidyl Peptidase Activity in Gingival Crevicular Fluid and Periodontal Attachment Loss in Chronic Periodontitis Patients. A 2-Year Longitudinal Study. *Journal of Periodontology* 67, 703-716.
- 10 Eley B.M. and Cox S.W. (2003) Proteolytic and hydrolytic enzymes from putative periodontal pathogens: characterization, molecular genetics, effects on host defences and tissues and detection in gingival crevice fluid. *Periodontology* 2000, 31, 105-124.
- 15 Jin L.J., Söder P-Ö., Leung W.K., Corbet E.F., Samaranayake L.P., Söder B. and Davies W.I.R. (1999) Granulocyte elastase activity and PGE2 levels in gingival crevicular fluid in relation to the presence of subgingival periodontopathogens in subjects with untreated adult periodontitis. *Journal of Clinical Periodontology* 26, 531-540.
- 20 Johansson A., Sandström G., Claesson R., Hänström L., Kalfas S. (2000) Anaerobic neutrophil-dependent killing of *Actinobacillus actinomycetemcomitans* in relation to the bacterial leukotoxicity. *European Journal of Oral Sciences* 108, 136-149.
- 25 Lamster I.B., Smith Q.T., Celenti R.S., Singer R.E. and Grbic J.T. (1994) Development of a risk profile for periodontal disease: microbial and host response factors. *Journal of Periodontology* 65 (5 Suppl), 511-20.
- 30 Nakagawa, T., Sims, T., Fan, Q., Potempa, J., Travis, J., Houston, L. and Page, R.C. (2001) Functional characteristics of antibodies induced by Arg-gingipain (HRgpA) and Lys-gingipain (Kgp) from *Porphyromonas gingivalis*. *Oral Microbiology and Immunology* 16 (4), 202-211.

'04 01/30 14:26 FAX +46 31630263

AWAPATH&T

→ PRV KASSAN

025

+46 31630263

Ink. t. Patent- och reg.verket

2025 RELEASE UNDER E.O. 14176

23 Huvudlägen Kossan

Nisengard R.J., Mikulski L., McDuffie D. and Bronson p. (1992) Development of a rapid latex agglutination test for periodontal pathogens. Journal of Periodontology 63 (7), 611-617.

5 Oringer R.J. (2002) Modulation of the Host Response
in Periodontal Therapy. Journal of Periodontology 73,
460-470.

Socransky S.S., Smith C., Martin L., Paster B.J.,
Dewhirst F.E. and Levin A.E. (1994) "Checkerboard" DNA-
DNA hybridization. Biotechniques 17 (4), 788-92.

12
13
14
15
16
17
18
19
20

+46 31630263

Ink. f. Patent- och registrer

... -71- 3 0

24

Huvudtaven Kassan

CLAIMS

1. A test kit for detecting periodontal disease in a patient by analysing a sample from the oral cavity of the patient, wherein said kit at least comprises:
 - 5 a first detection assay for detecting a first substance originating from bacteria, and
 - a second detection assay for detecting a second substance originating from the immune or inflammatory system 10 of the patient.
2. A test kit according to claim 1, wherein said first detection assay comprises at least a first affinity ligand having a binding site for binding said first substance originating from bacteria, and
 - 15 said second detection assay comprises at least a second affinity ligand having binding site for binding said second substance originating from the immune or inflammatory system of the patient.
- 20 3. A test kit according to claim 1 or 2, wherein said first substance is a bacterial virulence product.
4. A test kit according to claim 3, wherein said first substance is an enzyme.
 - 25 5. A test kit according to claim 4, wherein said enzyme is a protease.
 - 30 6. A test kit according to claim 5, wherein said protease is selected from the group consisting of arg gingipain from *Porphyromonas gingivalis* and a 48 kDa protease from *Bacteroides forsythus*.
 - 35 7. A test kit according to claim 3, wherein said first substance is a toxin.

+46 31630263

Ink. 1. Patent- och registreringsverket

M 01-30

25 Huvudlaxen Kassan

8. A test kit according to claim 7, wherein said toxin is a leukotoxin from *Actinobacillus actinomycetemcomitans*.

5 9. A test kit according to any of the preceding claims, wherein said second substance is a leukocyte product.

10. A test kit according to claim 9, wherein said leukocyte product is a natural serine protease.

11. A test kit according to claim 10, wherein said natural serine protease is a human neutrophil elastase.

15 12. A test kit according to any of the claims 1-8, wherein said second substance is a cytokine.

13. A test kit according to claim 12, wherein said cytokine is an interleukin.

20 14. A test kit according to claim 13, wherein said interleukin is chosen from among interleukin-1 β , interleukin-6 and interleukin-8.

25 15. A test kit according to claim 12, wherein said cytokine is an inflammatory mediator.

30 16. A test kit according to claim 15, wherein said inflammatory mediator is selected from the group consisting of tumour necrosis factor- α and prostaglandin E₂.

35 17. A test kit according to any of the claims 2 to 16, wherein said first affinity ligand is a first antibody exhibiting selective binding of said first substance and said second affinity ligand is a second antibody exhibiting selective binding of said second substance.

04 01/30 14:26 FAX +46 31630263

AWAPATENT

+46 31630263

Ink. f. Patent- och Tekniskt
PRV KASSAN

029

7304 -61- 3 0

Huvudfaxen Kassan

27

25. A method according to claim 24, wherein said first substance is a bacterial virulence product.

26. A method according to claims 25, wherein said 5 first substance is an enzyme.

27. A method according to claim 26, wherein said enzyme is a protease.

10 28. A method according to claim 27, wherein said protease is selected from the group consisting of arg-gingipain from Porphyromonas gingivalis and a 48 kDa protease from Bacteroides forsythus.

15 29. A method according to claim 25, wherein said first substance is a toxin.

30. A method according to claim 29, wherein said toxin is a leukotoxin from Actinobacillus 20 actinomycetemcomitans.

31. A method according to any of the claims 24-30, wherein said second substance is a leukocyte product.

25 32. A method according to claim 30, wherein said leukocyte product is a natural serine protease.

33. A method according to claim 32, wherein said natural serine protease is a human neutrophil elastase.

30 34. A method according to any of the claims 24-30, wherein said second substance is a cytokine.

35. A method according to claim 36, wherein said cytokine is an interleukin.

04 01/30 14:27 FAX +46 31630263

AWAPATENT

→ PRV KASSAN

032

+46 31630263

Ink. f. Patent- och ren. verket

1/1

2004-01-30

Huvudfaxes Kassan




Fig. 1

P
at
ch
O
n
G
a
s

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:**

**IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image
problems checked, please do not report these problems to
the IFW Image Problem Mailbox.**